Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption. Across healthcare, AI-enabled diagnostic solutions are flooding the market. From cardiology and imaging to oncology and primary care, clinicians are being asked to evaluate algorithms that promise earlier detection, better accuracy, and more efficient care. Many of these tools are technically impressive. Some are FDA-cleared. A few even come with early clinical data. Yet only a relatively small number have become part of routine clinical practice.
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Related Articles
Anumana Welcomes Dr. Simos Kedikoglou as New COO
Investor Hangout: Anumana, a prominent player in AI-driven health technology, has recently appointed Dr. Simos Kedikoglou as its new President and Chief Operating Officer (COO). This exciting change will see…January 10, 2025
New Philips platform offers AI-powered ECG tools from outside vendors
Royal Philips has launched the Philips ECG AI Marketplace, which gives cardiac care teams access to multiple vendor offerings in one central location. The company hopes this can help clinicians…July 25, 2025
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to itsAI-enhanced, ECG-basedPulmonary Hypertension(PH) Early…May 23, 2022
AI specialists ink deal with Pfizer to target cardiac amyloidosis
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has announced a new multi-year deal with Pfizer focused on improving the identification and diagnosis of cardiac…December 20, 2022


